Barclays PLC Buys 61,486 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)

Barclays PLC lifted its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 325.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 80,407 shares of the company's stock after purchasing an additional 61,486 shares during the period. Barclays PLC owned about 0.29% of GeneDx worth $6,180,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. MCF Advisors LLC lifted its holdings in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after purchasing an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock worth $27,000 after buying an additional 316 shares during the period. Global Retirement Partners LLC purchased a new position in GeneDx in the 4th quarter valued at approximately $28,000. KLP Kapitalforvaltning AS bought a new stake in GeneDx during the 4th quarter valued at $200,000. Finally, Evolution Wealth Advisors LLC purchased a new stake in shares of GeneDx during the fourth quarter worth $202,000. Institutional investors own 61.72% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on WGS shares. The Goldman Sachs Group boosted their price objective on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research note on Wednesday, February 19th. TD Cowen raised their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, GeneDx currently has an average rating of "Moderate Buy" and an average target price of $72.33.

Insider Activity at GeneDx

In related news, CEO Katherine Stueland sold 2,731 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $94.73, for a total transaction of $258,707.63. Following the transaction, the chief executive officer now owns 7,752 shares of the company's stock, valued at approximately $734,346.96. This trade represents a 26.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Feeley sold 15,516 shares of the company's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $92.18, for a total transaction of $1,430,264.88. Following the sale, the chief financial officer now owns 1,726 shares of the company's stock, valued at approximately $159,102.68. The trade was a 89.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 136,848 shares of company stock valued at $12,755,813. Corporate insiders own 27.30% of the company's stock.

GeneDx Price Performance

Shares of WGS traded down $2.74 during trading hours on Thursday, reaching $64.12. 1,320,415 shares of the company's stock traded hands, compared to its average volume of 710,433. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The firm's 50 day simple moving average is $95.53 and its 200-day simple moving average is $82.50. The stock has a market cap of $1.80 billion, a PE ratio of -33.06 and a beta of 1.93. GeneDx Holdings Corp. has a 12 month low of $16.65 and a 12 month high of $117.75.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The firm had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. Equities analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.